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Ferulic acid is a phenolic acid widely distributed in the plant kingdom. It presents a wide range of potential 
therapeutic effects useful in the treatments of cancer, diabetes, lung and cardiovascular diseases, as well as 
hepatic, neuro and photoprotective effects and antimicrobial and anti-inflammatory activities. Overall, the 
pharmaceutical potential of ferulic acid can be attributed to its ability to scavenge free radicals. However, 
recent studies have revealed that ferulic acid presents pharmacological properties beyond those related 
to its antioxidant activity, such as the ability to competitively inhibit HMG-CoA reductase and activate 
glucokinase, contributing to reduce hypercholesterolemia and hyperglycemia, respectively. The present 
review addresses ferulic acid dietary sources, the pharmacokinetic profile, antioxidant action mechanisms 
and therapeutic effects in the treatment and prevention of various diseases, in order to provide a basis 
for understanding its mechanisms of action as well as its pharmaceutical potential.
Uniterms: Ferulic acid/properties. Ferulic acid/antioxidant activity. Ferulic acid/dietary sources. Ferulic 
acid/therapeutic effects. Natural products. Pharmacognosy.
O ácido ferúlico é um ácido fenólico amplamente distribuído no reino vegetal. Ele apresenta uma ampla 
gama de potenciais efeitos terapêuticos utéis no tratamento do câncer, diabetes, doenças pulmonares e 
cardiovasculares, bem como efeitos hepáticos, neuro e fotoprotetores, atividades antimicrobianas e anti-
inflamatórias. O potencial farmacêutico do ácido ferúlico pode ser atribuído à sua capacidade em sequestrar 
radicais livres. No entanto, estudos recentes revelaram que o ácido ferúlico apresenta propriedades 
farmacológicas, além da sua atividade antioxidante, como a capacidade de inibir competitivamente 
a HMG-CoA redutase e ativar a glucoquinase, contribuindo para reduzir a hipercolesterolemia e 
hiperglicemia, respectivamente. A presente revisão aborda as fontes dietéticas de ácido ferúlico, o perfil 
farmacocinético, os mecanismos de ação como antioxidante e efeitos terapêuticos no tratamento e 
prevenção de várias doenças, de modo a proporcionar uma base para a compreensão dos seus mecanismos 
de ação, bem como os seus potenciais farmacêuticos.
Unitermos: Ácido ferúlico/propriedades. Ácido ferúlico/atividade antioxidante. Ácido ferúlico/fontes 
dietéticas. Ácido ferúlico/efeitos terapêuticos. Produtos naturais. Farmacognosia.
INTRODUCTION
Natural antioxidants exhibit therapeutic potential 
for a variety of diseases such as cancer, diabetes, and 
cardiovascular and neurodegenerative diseases (Kayahara 
et al., 1999; Kim et al., 2003; Soobrattee et al., 2005) 
where free radicals play a key role in development (Prior 
et al., 1998). Recently there has been increased public and 
scientific interest in employing natural antioxidants instead 
of synthetic antioxidants, due to their potential adverse 
effects on health which may include carcinogenicity (Ito 
et al., 1983; Würtzen, 1990; Osawa et al., 1990).
Antioxidants found in vegetables can act as 
sequesters, reducing agents, enzyme inhibitors, metal 
chelators or free radical scavengers (Wang et al., 2000). 
Phenols are widely distributed in the plant kingdom 
and diet vegetables. There are found in significant 
concentrations in fruits, vegetables and beverages and 
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have been indicated as effective antioxidants (Clifford, 
1999; Pimentel et al., 2005).
Ferulic acid (Figure 1) is one of the most abundant 
phenolic acids in plants and might be found in high 
concentrations in foods such as navy bean, corn bran, 
wheat bran, eggplant, artichokes and beets (Rosazza 
et al., 1995; Kroon et al., 1997; Rechner et al., 2001; 
D’archivio et al., 2007). It can be found free, dimerized 
or esterified with proteins and polysaccharides in the cell 
wall, such as arabinoxylans in grasses and xyloglucans in 
bamboo (Iiyama et al., 1994; Rumbold et al., 2003; Fazary, 
Ju, 2007). Ferulic acid (FA) is an important biological 
and structural component of the plant cell wall. Due to 
its ability to stop radical chain reactions by resonance 
followed by polymerization, FA offers protection 
against UV-radiation and is responsible for cross-linking 
polysaccharides and other cell wall polymers (Sánchez et 
al., 1996; Kroon et al., 1999, Santos et al., 2008).
FA can be obtained from plant cell walls via alkaline 
chemical (Taniguchi et al., 1999) or biotechnological 
treatments employing feruloyl esterases (EC 3.1.1.73) 
a subclass of the carboxylesterases produced by 
microorganisms that are able to hydrolyze ester bonds 
formed between cell wall polysaccharides and FA or 
its dimers, but more research is necessary to make 
biotechnological route economically attractive (Faulds et 
al., 1997; Kroon et al., 1999; Wong, 2005; Damásio et al., 
2012). These enzymes have been produced and purified 
from a wide range of microorganisms, including bacteria 
and fungi such as Pseudomonas fluorescens, Penicilium 
funiculosum, Talaromyces stipitatus, Aspergillus niger 
(Faulds et al., 1995; De Vries et al., 2002).
FA has received great attention in oriental research 
where it has been used as an antioxidant in food additives 
in Japan (Itagaki et al., 2009) and especially in medical 
studies in China after being proven to be an effective 
component of medicinal herbs used by Chinese traditional 
medicine, such as Angelica sinensis, A. cimicifuga and A. 
heracleifolia lignsticum chuangxiong (Sakai et al., 1999). 
FA can be absorbed by the small intestine and excreted 
in the urine, where therapeutic efficacy is dependent on 
its physiological concentrations and pharmacokinetic 
properties, which include absorption, distribution, 
metabolism and excretion of metabolites (Choudhury 
et al., 1999). The present article updates the therapeutic 
properties of FA, reviewing its sources, mechanisms of 
action and pharmacokinetics in order to provide concise 
information for researchers interested in the field.
NATURAL SOURCES
FA[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic 
acid] may be found as a monomer, dimer, free oligomer or 
making up polymers, covalently linked by ester bonds with 
polysaccharides, polyamines and glycoproteins, as well as 
ether linked to lignin (Durán, Padilla, 1993; Bourne, Rice-
Evans, 1998; Kroon et al., 1999). FA has two isomers: 
cis (yellow oily liquid) and trans (white crystal), the last 
corresponding to 90% of its natural occurrence (Fulcher, 
1983). It is synthesized in the shikimate/phenylpropanoid 
pathway mainly from L-phenylalanine, or in grasses 
from L-tyrosine (Figure 2). The phenylpropanoid path 
starts with deamination of L-phenylalanine to produce 
cinnamic acid, a reaction catalyzed by phenylalanine 
ammonia-lyase (PAL). Cinnamic acid is hydroxylated 
to give p-coumaric acid, in a reaction catalyzed by 
cinnamate 4-hydroxylase (C4H). Alternatively, L-tyrosine 
deamination, catalyzed by tyrosine ammonia lyase (TAL) 
directly produces p-coumaric acid (Castelluccio et al., 
1995). p-Coumaric acid is then esterified to coenzyme A 
by the enzyme 4-coenzyme A ligase (4CL), transesterified 
with shikimate or quinate by hydroxycinnamoyl CoA: 
quinate/shikimate hydroxycinnamoyl transferase (HCT) 
and further hydroxylated in carbon 3 to produce cafeoyl-
shikimate/quinate ester by the enzyme coumaroyl-
3-hydroxylase (C3H). Caffeoyl-shikimate/quinate is 
transesterified with CoA and the hydroxyl in C3 is 
methylated by cinnamoyl-coenzyme A orthomethyl 
transferase to produce feruloyl-CoA. The ester may be 
exported to feruloylate polysaccharides in Golgi apparatus 
by action of a putative feruloyl transferase or released as 
coniferaldehyde in a reaction mediated by cinnamoyl-
coenzyme A reductase (CCR). The free FA is produced 
by the subsequent oxidation of coniferaldehyde by the 
enzyme coniferyl aldehyde dehydrogenase (CALDH) 
(Chen, 2006).
High concentrations of FA may occur in common 
foods, such as corn bran (2610-3300 mg/100 g), wheat 
bran (1358-2293 mg/100 g), maize bran (3000 mg/100 g), 
banana (5.4 mg/100 g), bamboo shoots (243.6 mg/100 g), 
eggplant (25 mg/100 g), orange (9.2-9.9 mg/100 g), beets 
(800 mg/100 mg) as well as in broccoli, spinach, cabbage, 
potatoes, carrots, tomatoes, coffee, natural extracts of 
herbs and a range of fruits and vegetables (Kroon et al., 
FIGURE 1 - Chemical structure of ferulic Acid (FA).
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FIGURE 2 – Simplified phenylpropanoid pathway. PAL, phenylalanine ammonia-lyase; C4H, cinnamate-4-hydroxylase; 
4CL, 4-coumarate:CoA ligase; HCT, hydroxycinnamoyl CoA: quinate/shikimate hydroxycinnamoyl transferase; C3H, 
coumarate-3-hydroxylase; CCoAOMT, caffeoyl coenzyme A 3-O-methyltransferase; CCR, cinnamoyl CoA reductase; F5H, 
ferulate 5-hydroxylase; COMT, caffeic acid 3-O-methyltransferase; CAD, cinnamyl alcohol dehydrogenase; ALDH, aldehyde 
dehydrogenase (Santos et al., 2008).
1997; Zhao et al., 2005; Mattila et al., 2005; Matilla et al., 
2006; Liyana, Shahidi, 2006; Mattila et al., 2007).
The esters of hydroxycinnamic acids and quinic 
acid produced by HCT (Figure 2) are also generically 
named chlorogenic acids of which the most common is 
5-O-caffeoyl quinic acid (Clifford, 1999). It is present in 
particularly high concentrations in numerous foods and 
beverages such as coffee, pears, potato tubers and apple, 
and as a consequence in derived by-products. Analysis of 
the coffee pulp (the solid residue from coffee processing) 
indicated that chlorogenic acid (around 40%) is the main 
phenolic compounds (Pandey et al., 2000).
The industrial use of hydroxycinnamates has 
attracted growing interest for several years ever since 
they and their conjugates were shown to be bioactive 
molecules, possessing potential antioxidant activities and 
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health benefits. Extraction of these phenolic compounds 
from biomass through the breakdown of the ester 
linkages with polymers has allowed the exploitation of 
such compounds for pharmaceutical, industrial and food 
applications (Benoit et al., 2006).
Huang et al. (2011) obtained high concentrations 
of FA from lignocellulolytic agricultural waste (rice 
bran, wheat bran, corncob) employing an extracellular 
esterase (AXE) and xylanase (Tfx) from Thermobifida 
fusca NTU22. Corncob exhibited the best ferulic 
acid yield, where 396 µM accumulated in the culture 
broth. However, FA with purity greater than 98% was 
obtained from extracts of Radix Angelicae sinensis after 
microwave-assisted extraction (MAE) followed by high-
speed counter-current chromatography (HSCCC) (Liu et 
al., 2006).
PRECLINICAL PHARMACOKINETIC
A person can ingest from 80-165 mg of FA in a meal. 
FA is present in food in both conjugated and free forms 
(Rondini et al., 2004), and presents a very low toxicity. 
The acute oral LD50 of FA in male and female F344 rats 
was 2445 mg.kg-1 and 2133 mg.kg-1, respectively (Tada et 
al., 1999). Both free and linked FA are quickly absorbed 
from the stomach without modification due to acid pH, 
according to studies carried out in situ in the rat stomach, 
but it was verified that only the free form of the acid was 
absorbed by the intestine after administration of 8 µmol 
FA / kg body weight (Zhao et al., 2004).
Digestion of bound FA involves xylanases (EC 
3.2.1.8), feruloyl (EC 3.1.1.73) and cinnamoyl (EC 
3.1.1.1) esterases present in the gastro-intestinal tract 
of ruminants (Kroon et al., 1997). The absorption of FA 
occurs mainly in the colon by passive diffusion (c. 90%), or 
by active transport via the monocarboxylic acid transporter 
(MCT) (Poquet et al., 2008). Studies have shown a high FA 
absorption rate, with peak plasma concentration attained 
within 15-30 min after administration of FA. Only 0.5-
0.8% is found in feces of mice (Zhao et al., 2003). After 
absorption, about 50% of FA reaches the liver, and the 
remainder is distributed in the bloodstream, gastric mucosa 
and peripheral tissues (Adam et al., 2002; Zhao et al., 
2004; Silberberg et al., 2006).
Chang et al. (1993) administered pure FA in 
Wistar rats and found that the free acid did not enter 
the enterohepatic circulation. Conjugation was required 
for its distribution in the organism. The conjugation 
reactions of FA occur mainly in the liver but may also 
occur in the intestinal mucosa or kidney, catalyzed by 
sulfotransferases (EC 2.8.2.1) and UDP glucuronosyl 
transferases (EC 2.4.1.17) (Piskula, Terao, 1998; Kern et 
al., 2003; Zhao et al., 2004). Studies in humans and rats 
showed that after oral intake of FA, the most abundant 
metabolites generated in plasma were FA-glucuronide (FA 
conjugate with glucuronic acid) and FA-sulfoglucuronide 
(FA conjugate with sulfate and glucuronide) in addition to 
unmodified FA. The studies indicated that concentrations 
of metabolites derived from FA ingestion are a function 
of several factors such as the dose and route administered, 
as well as the animal species (Zhao et al., 2003, 2004).
Free phenolic acids can be absorbed via paracellular 
transport and active transport mediated by monocarboxylic 
acids transporters (MCT) in the gastrointestinal mucosa. 
According to Konishi et al. (2006) the absorption 
efficiency of each phenolic acid depends on its affinity 
for the MCT. To elucidate the different affinities, different 
phenolic acids were administered in the rats’ stomach 
at concentration of 2.25 mmol L-1, after which plasma 
concentrations were measured. The plasma concentration 
rate increased in the following order: gallic acid = 
chlorogenic acid <caffeic acid <p-coumaric acid = FA, 
which corresponds to their affinities to MCT. Peak levels 
of FA occur within 5 min after administration.
In rats, FA and its metabolites are predominantly 
excreted in urine, but about 4-6% of the ingested dose may 
be excreted through bile (Adam et al., 2002). Excretion 
may occur 1.5 h after administration of the acid (Rondini 
et al., 2002), while in humans only 7-9 h after consumption 
(Bourne, Rice-Evans, 1998). However, in both rats and 
humans the rate of unmodified FA recovered in urine is 
only 4-5% of the ingested acid (Bourne, Rice-Evans, 1998; 
Rondini et al., 2002). Urinary excretion of FA is influenced 
by its combination, where the elimination rate of the acid 
after consumption of wheat bran was 15 times slower than 
after the consumption of the free molecule (Rondini et 
al., 2002). Conclusive studies on pharmacokinetics and 
bioavailability of FA and its conjugated forms in humans 
are necessary so that it may be utilized as a nutrient 
supplement administered orally in its free form or bound 
to sugars in order to improve its absorption and interaction 
with target tissues, increasing its efficiency in preventing 
or treating chronic diseases.
RADICAL SCAVENGER PROPERTIES
Free radicals may be defined as organic and 
inorganic molecules or atoms which contain one or more 
unpaired, independently existing electrons (Halliwell, 
1994). They present short half-life and are very reactive. 
Found in all biological systems, they are continuously 
generated by several physiological processes from 
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either endogenous or exogenous sources. The activity of 
oxidases, dehydrogenases, peroxidases and the presence 
of transition metals in the cell give rise to free radicals 
and are considered to be endogenous sources. Tobacco, 
air pollution, organic solvents, anesthetics, pesticides, 
gamma and ultraviolet rays are examples of exogenous 
sources (Soares, 2002).
The uneven balance between oxidant and antioxidant 
molecules, which results in the induction of cell damage 
by free radicals, is referred to as oxidative stress (Sies, 
1993) and can trigger a series of chronic degenerative 
diseases such as arthritis, atherosclerosis, diabetes, 
cataracts, chronic inflammations, brain dysfunction, 
aging, cancer and others (Bianchi, Antunes, 1999). 
An antioxidant is defined as “any substance that when 
present in low concentrations compared to the oxidizable 
substrate effectively delays or inhibits the oxidation of 
the substrate”. In organisms, antioxidants are the agents 
responsible for inhibition and reduction of injuries caused 
by free radicals in cells (Sies, 1993; Sies, Stahl, 1995).
The antioxidant potential of FA can be attributed 
to the formation of a phenoxy radical from the phenolic 
nucleus. Due to its potential displacement in resonance 
structures, such a radical has low energy which generates 
a more stable hybrid resonance structure (Figure 3). In the 
reactive collision of FA with a free radical, the hydrogen 
atom of the acid is easily transferred to the radical, forming 
a phenoxy radical that is highly stabilized since the 
unpaired electron may be present not only on the oxygen 
but it can be delocalized across the entire molecule. 
This phenoxy radical is unable to initiate or propagate 
a radical chain reaction and its most probable fate is a 
collision and condensation with another radical, including 
another ferulate radical to yield the dimer curcumin and 
other dimers. The presence of the extended side chain 
enhances stabilization of the conjugated methoxy radical, 
because it is an unsaturated chain with the function of a 
carboxylic acid, but dimers and oligomers are still able to 
stop radical chain reactions. Additionally, this carboxylic 
acid group also acts as an anchor of FA by which it binds 
to the lipid bilayer, protecting against lipid peroxidation. 
In other words, the stable resonance structure of the 
phenoxy radical is responsible to cease propagation of 
any chain reaction initiated by free radicals, making 
FA especially able to scavenge and stop free radical 
chain reactions (Kanski et al., 2002; Graf, 1992). FA 
also presents “indirect” free radical scavenging activity, 
namely the ability of this phenolic acid to up-regulate the 
heme oxygenase-biliverdin reductase system (Calabrese et 
al., 2008; Barone et al., 2009; Fetoni et al., 2010), which 
in turn generates bilirubin, an endogenous free radical 
scavenger (Mancuso et al., 2006; Mancuso, Barone, 
2009b).
PHARMACOLOGICAL APPLICATIONS
Antioxidant agent
Intestinal ischemia is a disease that occurs in the 
absence or reduction of arterial blood flow and/or bowel 
venous malformation by acute or chronic obstruction of 
the arteries and/or visceral veins. It may be caused by a 
thrombus, stenosis - derived (or not) from atherosclerosis, 
a trauma or vasospasm induced by vasoactive drugs 
(Simi, 2002). Among the various mechanisms involved 
in causing intestinal lesions that result from ischemia 
and subsequent reperfusion, the generation of reactive 
oxygen species (ROS) through the hypoxanthine/xanthine 
oxidase system is a major factor causing intestinal damage. 
The free radicals generated act mainly in peroxidation 
of cellular membranes, inactivation of disulfide bond 
dependent enzymes, inhibition of ATP synthesis through 
DNA changes and the formation of several oxygen-derived 
residues, which have great reducing potential (Horton, 
Walker, 1993; Schoenberg, Beger, 1993; Yoshida, 1996). 
In order to investigate the protective effects of FA in 
intestine injuries resulting from ischemia-reperfusion, 
Itagaki et al. (2009) conducted in vivo assays using male 
Wistar rats to compare the antioxidant activity of ferulic 
acid with ascorbic acid and epigallocatechin gallate 
(EGCG).
Ascorbic acid and EGCG are compounds with 
high activity for elimination of the superoxide anion and 
inhibition xanthine oxidase. Mancuso and Barone (2009a) 
report the possibility that EGCG inhibits several drug 
metabolizing enzyme, thus increasing the potential toxic 
effects of xenobiotics. Previous studies have demonstrated 
that EGCG inhibits the growth of tumors of the liver and 
intestine (Nishida et al., 1994; Fujita et al., 1989). In these 
studies it was found that EGCG and ascorbic acid have 
protective effects on intestinal ischaemia–reperfusion injury 
in the small intestine of rats. Although combined antioxidant 
activity from radical scavenging and xanthine oxidase 
FIGURE 3 - Resonance stabilization mechanism of the FA 
radical.
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inhibition of FA was much weaker than the combined 
antioxidant activities of EGCG and ascorbic acid, treatment 
with FA also prevented an increase in vascular permeability 
caused by intestinal ischaemia-reperfusion, suggesting that 
it can be used as an ingredient in functional foods to enhance 
the effect of other protective compounds.
Kawata et al. (2000) investigated the protective 
effects of FA on rat colon carcinogenesis induced by 
azoxymethane (AOM). In one experiment it was verified 
that the group receiving FA doses of 250 and 500 ppm 
presented a lower incidence of colon carcinomas (23 and 
27% respectively) compared to group that received only 
AOM (59%). In another experiment, it was found that the 
FA influenced the activities of glutathione S-transferase 
and quinone reductase in the liver and colon when utilizing 
doses of 25, 50 and 100 mg FA/kg body weight. The higher 
dose significantly increased activity of both enzymes, 
suggesting that their detoxifying activities are related to 
the effect of FA on colon carcinogenesis induced by AOM.
Antimicrobial and anti-inflammatory agent
Studies performed in vitro for FA and ethyl ferulate 
(EF) activity on HIV revealed that these compounds 
reduced the release and activity of the p24 antigen, an 
essential protein from the virus capsid, after chronically 
infected cells were treated with 1, 5 and 10 μmol L-1 of FA 
or EF. FA and FE at 5 μmol L-1 inhibited the replication of 
the virus without cytotoxicity, suggesting that the FA and 
derivatives are potentially useful molecules for antiviral 
therapy (Edeas et al., 1995).
FA also inhibits growth of both Gram-positive and 
negative bacteria (Escherichia coli) and is already present 
in the composition of anti-inflammatory drugs used in 
Oriental Medicine (Jeong et al., 2000).
Hirabayashi et al. (1995) investigated the effects 
of FA and isoferulic acid (IFA), active components of 
the rhizome of Cimicifuga species (plants used as anti-
inflammatory agents in Japanese medicines) on murine 
interleukin-8 (IL-8) production in response to influenza 
virus infections in vitro and in vivo using the antibody-
sandwich enzyme-linked immunosorbent assay. IL-8 is a 
protein of the cytokine family which acts as a mediator in 
the inflammatory process which is also expressed in tumor 
cells. In the in vitro study, the murine macrophage cell line 
RAW 264.7 was infected with 10 PFU (plaque forming 
units) of the influenza virus and cultured in the presence 
or absence of phenolic acids. Levels of IL-8 were reduced 
after 20 h in the conditioned medium when compared with 
the control, but the effect of IFA was greater than that of 
FA: IL-8 levels were reduced to 43% and 56% (compared 
with control) in the presence of 100 mg/mL of IFA and FA, 
respectively. In the in vivo study, mice were infected with 
1 PFU of the virus and received daily oral administrations 
of the Cimicifuga heracleifolia extract (5 mg/mouse/day), 
FA (0.5 mg/mouse/day), IFA (0.125 mg/mouse/day), or 
phosphate buffered saline. All drugs presented a tendency 
to reduce IL-8 levels observed via bronchoalveolar 
lavage (BAL) two days after infection, and both acids 
significantly reduced the number of neutrophils exuded 
in BAL. Data indicates that these two compounds are the 
most active principles of the anti-inflammatory species 
obtained from Cimicifuga.
Hepatoprotective agent
The liver plays a key role in the detoxification and 
elimination of various harmful agents that can enter the 
organism through environmental or occupational exposure 
(Vander et al., 1994). But it also can suffer damage from a 
variety of hepatotoxins, such as excessive alcohol intake, 
heavy metals, and organic and inorganic solvents, resulting 
in excessive generation of free radicals which cause 
hepatotoxic lesions including acute hepatitis, cirrhosis, 
portal fibrosis and hepatic carcinoma (Vander et al., 1994; 
Tolman, Sirrine, 1998; Nakagiri et al., 2003). Rukkumani 
et al. (2004) evaluated the hepatoprotective effect of FA 
on the toxicity induced by alcohol and poly-unsaturated 
fatty acids in female Wistar rats by administering (orally) 
ethanol and sunflower oil at the level of 40 mg FA/kg body 
weight for 45 days. The enzymes alkaline phosphatase, 
glutamyl transferase, alanine aminotransferase and 
aspartate aminotransferase presented significantly 
decreased activities after treatment with FA. Enzymes 
with antioxidant activity, such as superoxide dismutase, 
catalase, and glutathione peroxidase presented significantly 
lower activity in rat livers receiving pure ethanol, pure 
sunflower oil and both. However, in the liver of rats given 
FA doses, the activities of these enzymes were increased 
and the reduction of oxidative stress was most significant 
in the lowest dose (20 mg FA/kg body weight). These 
positive results suggest that FA is a hepatoprotective agent 
against toxins commonly ingested in the diet and it has the 
advantage of showing no side effects. Therefore it may be 
considered a potential molecule for alternative treatments 
of liver damage. Shanmugarajan et al. (2008) further 
evaluated the protective effects of FA on D-galactosamine, 
a hepatotoxin employed in studies involving liver disease, 
because it causes damage (necrosis) similar to the injury 
resultant of viral hepatitis in humans (Shi et al., 2008). 
The results showed that the group of male Wistar rats that 
received pre-treatment (20 mg FA/kg body weight) had 
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increased activity of antioxidant enzymes in liver tissue, 
significant inhibition of lipid peroxidation and decreased 
levels of cholesterol, triglycerides and free fatty acids in 
relation to the control group.
FA also has a hepatoprotective effect against toxicity 
induced in vivo by carbon tetrachloride, as reported 
by Srinivasan et al. (2005). Treatment with the acid 
significantly decreased the index of lipid peroxidation 
in the liver and significantly increased the activities of 
superoxide dismutase, catalase and glutathione peroxidase. 
Yeh and Yen (2006) investigated the modulatory 
effects of FA in the in vivo system, where mice received 
a dose of 100 mg FA/kg body weight for 14 days. The 
activities of hepatic superoxide dismutase, glutathione 
peroxidase and catalase were higher after administration 
of FA when compared with the control group (P<0.05), 
and liver homogenates of rats treated with FA had a greater 
oxygen radical absorption capacity than the control group.
K i m  e t  a l .  ( 2 0 11 )  a l s o  i n v e s t i g a t e d  t h e 
hepatoprotective effect of FA against carbon tetrachloride 
(CCl4)-induced acute liver injury. Mice were treated 
intraperitoneally with the vehicle or FA (20, 40, and 
80 mg/kg) 1 h before and 2 h after CCl4 injection 
(20 µL/kg), followed by serum analysis. Pretreatment with 
FA attenuated the increase in aminotransferase activities, 
hepatic level of malondialdehyde, serum level and 
mRNA expression of tumor necrosis factor-α, the levels 
of inducible nitric oxide synthase and cyclooxygenase-2 
proteins, as well as mRNA expression. FA significantly 
attenuated the increase in levels of phosphorylated JNK 
and p38 mitogen-activated protein (MAP) kinase, as well 
as nuclear translocation of activated c-Jun. While acute 
CCl4 challenge induced the TLR4, TLR2, and TLR9 
proteins and mRNA expression, FA significantly inhibited 
TLR4 expression. This study provides evidence that FA 
may offer an alternative for prevention of acute liver 
diseases, because it prevents CCl4-induced hepatotoxicity 
by suppression of oxidative stress and inflammatory 
signaling pathways. These studies show that FA can also be 
used for protection and treatment of liver damage caused 
by drugs, viruses or metabolic disorders.
Recently, Ramar et al. (2012) investigated the effect 
of FA and resveratrol on alloxan-induced diabetic mice, 
through analysis of basic biochemical parameters, enzyme 
activities, lipid peroxidation and immunohistochemical 
studies. In this study FA was administrated orally to 
alloxan-induced diabetic mice at the concentration of 
10 mg FA/kg body weight and 20 mg resveratrol/kg 
body weight. The diabetic mice treated with FA and 
resveratrol exhibited smaller levels of lipid peroxidation, 
higher levels of antioxidants in the liver, kidney and 
serum, and a marked decrease in the immunoreactivity 
of the nuclear transcription factor (NF-κB) compared to 
untreated diabetic mice. These results showed that FA and 
resveratrol exerted antioxidant and anti-diabetic effects, 
probably through inhibition of the proinflammatory 
and NF-κB factors, reducing liver, kidney and pancreas 
damage caused by alloxan-induced diabetes.
Anti-diabetic agent
The metabolic disease Diabetes Mellitus (DM) 
which presents a multifactorial origin and increased 
oxidative stress has been indicated as playing a central role 
in these disorders (Reis et al., 2008; Sharma et al., 2005). 
Evidence suggests that oxidative cell injury caused by free 
radicals contributes to the development of complications 
in type 1 diabetes (T1DM) and reduces enzymatic and 
non-enzymatic antioxidant defenses (Reis et al., 2008).
In vivo studies have shown that FA has the ability 
to neutralize free radicals present in the pancreas induced 
by streptozotocin. Female Wistar rats received 10 and 
40 mg of FA/kg body weight for 45 days. The result was 
an increase in body weight of 61% in the group given the 
lowest dose and 52% in the group receiving the highest 
dose. Furthermore, blood glucose levels decreased 60% 
for the high dose compared to the group of diabetic rats that 
did not receive FA. Activities of the antioxidant enzymes 
superoxide dismutase, catalase and glutathione peroxidase 
were higher in the liver of the diabetic rats which received 
FA doses compared to the untreated diabetic group. This 
study shows that the elimination of free radicals facilitates 
the proliferation of β-cells that secrete insulin, which in turn 
enhance the use of glucose by extra hepatic tissues, thus 
reducing blood glucose levels (Balasubashini et al., 2004).
Noumura et al. (2003) reported that amides derived 
from FA also influence the increase in insulin secretion 
by pancreatic β-cells. Studies performed in rats have 
shown that administration of the derivatives at a dose 
of 0.01% to 0.1% of the base diet decreased levels of 
glucose in diabetic rats induced by streptozotocin. In a 
study performed by Ohnishi et al. (2004) with KK-Ay 
mice, the dose of 0.05% FA effectively suppressed blood 
glucose levels and reduced lipid peroxidation in adipose 
tissue, indicating that FA may be useful in the reduction of 
oxidative stress and hyperglycemia in individuals suffering 
from DM. Subsequently, Jung et al. (2007) demonstrated 
in studies using diabetic mice that FA increases the activity 
of the enzyme glucokinase, a key enzyme in the regulation 
of blood glucose levels.
Adisakwattana et al. (2009) investigated the 
inhibitory activity of cinnamic acid derivatives against rat 
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intestinal α-glucosidase and porcine pancreatic α-amylase 
in vitro in order to find effective inhibitors from natural 
sources that could be used in prevention and treatment of 
DM. Inhibition of α-glucosidase and α-amylase delays 
the digestion of starch and disaccharides to absorbable 
monosaccharides, resulting in a reduction of postprandial 
hyperglycemia. Among the cinnamic acids tested, caffeic 
acid, FA and IFA were the most potent inhibitors against 
intestinal maltase, while IFA and FA were effective 
inhibitors of intestinal sucrase. However, all cinnamic 
acid derivatives were found to be inactive with respect to 
pancreatic α-amylase inhibition. Such studies are useful in 
developing treatments for diabetes as well as prevention.
Anti-cholesterolemic agent
Kim et al. (2003) showed that FA has the ability to 
reduce the level of low density lipoproteins in rats. It was 
suggested that synthesis of cholesterol was decreased 
by competitive inhibition of hydroxymethylglutaryl 
coenzyme A reductase (HMG-CoA reductase) by FA. 
This enzyme is the most important regulatory step in the 
biosynthesis of cholesterol in the organism catalyzing 
the synthesis of mevalonic acid. In another in vivo study, 
conducted by Yogeeta et al. (2006), it was reported that 
pretreatment with FA at a dose of 20 mg/kg body weight 
and ascorbic acid at a dose of 80 mg/kg body weight in 
rats intoxicated with isoproterenol significantly reduced 
levels of triglycerides, total cholesterol, cholesterol 
esters and free fatty acids in serum and heart tissues. Also 
observed was a decrease in the levels of phospholipids, 
lipid peroxides and low density lipoproteins. This 
study confirmed the action of two antioxidants in lipid 
metabolism and the synergistic effect between them.
Recently, Kwon et al. (2010) studied the anti-
atherogenic effects of FA by administering 0.02% 
FA (w/w) compared to clofibrate (0.02%, w/w) in 
apolipoprotein E-deficient [apo E(-/-)] mice. Clofibrate 
reduces cholesterol and triglycerides in the blood. The 
results revealed that concentrations of total cholesterol 
(total-C) and apolipoprotein B (apo B) in plasma and 
adipose tissue were significantly lower in the group that 
received FA or clofibrate, and that there was no formation 
of fatty plaques in the aorta compared to the control 
group. The activities of antioxidant enzymes (superoxide 
dismutase, catalase, glutathione peroxidase, glutathione 
reductase and paraoxonase) in the hepatocyte and 
erythrocyte were significantly higher in the FA group than 
in the control group, and the hepatic TBARS level was only 
slightly lower in the FA group. This study demonstrated 
that FA is as effective as clofibrate for reducing cholesterol 
and deserves attention due to its anti-atherogenic property 
in apo E(-/-) mice fed with a Western diet.
Neuroprotective agent
In another study performed by Kanski et al. (2002), 
the presence of FA in neuronal cell systems exposed to 
peroxyl and hydroxyl radicals reduced damage in the cells 
without causing its death, proving to be more potent than 
vanillic acid, coumaric acid and cinnamic acid. Analysis 
using the electron paramagnetic resonance technique 
in synaptosomal membrane proteins indicated that the 
protection provided by FA against free radicals is mediated 
by conformational changes in these proteins.
Parkinson’s disease (PA) and Alzheimer’s disease 
(AD) are neurodegenerative diseases associated with 
chronic inflammation caused by oxidative stress resulting 
from ROS and reactive nitrogen species. These oxidative 
species affect activity of essential proteins, injure RNA 
and DNA, and induce lipid peroxidation resulting in 
neuronal dysfunction (Barnham et al., 2006; Joshi et 
al., 2006). AD is characterized by neuronal loss, diffuse 
cortical atrophy, the presence of large numbers of senile 
plaques and neurofibrillary tangles, bead-vacuolar 
degeneration, neuronal loss, accumulation of β-amyloid 
proteins in senile plaques and disorders of the transmission 
of acetylcholine and acetyltransferases (Katzman, 1986; 
Mancuso et al., 2007). The production of free radicals and 
neuroinflammation contribute to the destruction of some 
brain regions such as the cortex (Mancuso et al., 2007). 
Thus, FA can have a favorable effect on AD due to its 
anti-inflammatory and antioxidant properties (Graf, 1992; 
Kanski et al., 2002).
Ono et al. (2005) evaluated the ability of FA to inhibit 
formation of β-amyloid fibrils (fAβ) and the destabilization 
of existing fibrils when compared with the results obtained 
in vitro in previous studies with curcumin, rifampicin and 
tetracycline. Using fluorescence spectroscopic analysis 
with thioflavin T and electron microscopy, fAβ at pH 7.5 
and 37 °C was analyzed. FA dose-dependently inhibited 
the formation of fAβ and destabilized fAβs already 
formed. The activity of all the molecules examined was 
curcumin (a diferulate) >FA>rifampicin=tetracycline. 
Inhibition of fAβ and destabilization of preformed fAβ 
in the central nervous system are attractive therapeutic 
targets for the treatment of AD, making FA an interesting 
molecule in studies toward development of a therapeutic 
treatment. In studies performed in vivo by Yan et al. 
(2001), mice were pretreated by ingesting pure water or 
that containing FA (0.006%). After 4 weeks, 410 pmol 
of β-amyloid peptide (Aβ1-42) was administered via 
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intracerebroventricular injection. Pretreatment with FA 
significantly reduced neuroinflammation, which was 
assessed using the glial fibrillary acidic protein (GFAP) 
as a biochemical marker for gliosis and interleukin-1 β 
(IL-1β) in the hippocampus, indicating that the prolonged 
delivery of FA induces resistance to toxicity caused by 
Aβ1-42 in the brain and may be a useful chemopreventive 
agent against AD. Sultana et al. (2005) also found that 
ethyl ferulate (eFA) has a protective effect against 
neurotoxicity induced by Aβ1-42. In the pretreatment of 
primary hippocampal cultures with 10-50 mmol L-1 eFA, 
cytotoxicity, intracellular accumulation of ROS, protein 
oxidation and lipid peroxidation induced by Aβ1-42 were 
decreased. The study shows that the derivative of FA, eFA, 
may be a key molecule in the therapeutic treatment of AD 
and other diseases related to oxidative stress.
Anticarcinogenic agent
Reactive oxygen species are considered a significant 
class of carcinogens, participating in the initiation, 
progression and metastasis of neoplasm. ROS generated 
in the intracellular environment can directly produce 
alterations in simple or double stranded DNA, leading to 
mutagenesis (Ames, 1983). Large amounts of hydrogen 
peroxide are produced and secreted by tumor cells, 
confirming its importance in spreading and invasion of the 
tumor (Szatrowski, Nathan, 1991). Anti-cancer activity of 
FA is related to its antioxidant property to eliminate ROS 
and stimulate the activity of antioxidant enzymes (Hirose 
et al., 1999).
Mori et al. (1999) studied the effects of FA on oral 
cancer after causing chemically induced carcinogenesis 
in rats using 4-nitroquinoline 1-oxide (4NQO), exposing 
them to drinking water containing 0.02 g 4NQO/kg for 5 
weeks and after this period subjecting them to 0.5 g FA/kg 
body weight. It was found that the incidence of carcinomas 
on the tongue and preneoplastic lesions were significantly 
lower in the group receiving the dose of FA than the control 
group, suggesting that the FA possess chemopreventive 
activity against oral cancer. In another study performed by 
Kawabata et al. (2000), the effects of FA administered to 
the mice diets were examined after induced carcinogenesis 
in the colon by azoxymethane (AOM). After 35 weeks, 
the group that received doses of 0.25 and 5 g FA/kg body 
weight presented a lower incidence of colon carcinomas in 
relation to the group that received merely AOM. It was also 
observed that the enzymes responsible for detoxification of 
the liver and colon, glutathione S-transferase and quinone 
reductase, showed increased activities in mice treated with 
FA, suggesting these enzymes are directly related to the 
blocking effect caused by FA in carcinogenesis induced 
by AOM.
Alias et al. (2009) evaluated and compared the 
chemopreventive potential of topically applied and orally 
administered FA against 7,12-dimethylbenz[a]anthracene 
(DMBA)-induced skin carcinogenesis, estimating the 
status of phase I and phase II detoxification agents, lipid 
peroxidation byproducts and antioxidants. Skin squamous 
cell carcinoma was induced on the shaved back of mice, 
by painting with DMBA (25 μg in 0.1 mL acetone) twice 
weekly for 8 weeks. Oral administration of FA completely 
prevented the formation of skin tumors and reverted the 
status of phase I and phase II detoxification agents, lipid 
peroxidation byproducts and antioxidants to near-normal 
range in DMBA-treated mice. However, when topically 
applied, FA did not show significant chemopreventive 
activity during DMBA-induced skin carcinogenesis in 
the mice. The results demonstrate that orally administered 
FA has a potent suppressing effect on cell proliferation 
during DMBA-induced skin carcinogenesis, probably due 
to its modulating effect on the status of lipid peroxidation, 
antioxidants and detoxification agents during DMBA-
induced skin carcinogenesis.
Another recent study using Sprague–Dawley rats 
evaluated the FA chemopreventive potential by monitoring 
the incidence of tumors as well as analyzing phase II 
detoxification enzymes during mammary carcinogenesis 
induced by DMBA. Oral administration of FA at a dose of 
40 mg/kg body weight prevented tumor formation in 80% 
of the rats (Baskaran et al., 2010). Although there is no 
detailed mechanism of the process, the modulatory effect 
of FA on the phase II detoxification cascade could play a 
possible role and it deserves attention due to its therapeutic 
potential in preventing mammary cancer.
UV protection agent
Saija et al. (2000) conducted in vitro and in vivo 
studies which proved the effectiveness of FA in combating 
skin damage caused by ultraviolet rays. They also showed 
that absorption of FA through the skin is not influenced 
by the pH of the lotion formulation, suggesting that FA 
can be used in the composition of lotions to combat 
photoaging. Murakami et al. 2002 further demonstrated 
that a derivative from FA, FA15 (2-methyl-1-butyl ferulic 
acid) is also a chemopreventive agent. In tests performed 
in vitro, FA15 markedly suppressed the combined 
lipopolysaccharide and interferon-gamma-induced 
protein expressions of inducible nitric oxide synthase and 
cyclooxygenase-2, and also inhibited the release of tumor 
necrosis factor-α accompanied by suppression of I-κappa 
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B degradation in RAW264.7, a murine macrophage cell 
line. In tests conducted in vivo on mouse skin, topical 
application of FA15 caused a decrease in the production 
of hydrogen peroxide and edema formation caused by 
ultraviolet radiation while application of FA did not. These 
results suggest that FA15 is a novel chemopreventive 
agent, both structurally and functionally.
FA can be used as an additive in sunscreens available 
on the market to increase photoprotection of the skin, hair 
and combat premature and natural aging according to 
studies conducted by Lin et al. (2008). Pig skin was treated 
with five well-known isoflavone compounds (genistein, 
equol, daidzein, biochanin A, and formononetin) and one 
antioxidant combination solution of 15% vitamin C, 1% 
vitamin E and 0.5% FA daily for 4 days. Skin was irradiated 
with solar-simulated UV irradiation, 1 to 5 minimal erythema 
dose (MED) at 1-MED intervals. Topical application of 
0.5% solutions of the three individual phytoestrogens – 
genistein, daidzein and biochanin A, showed less protection 
than that provided by the antioxidant mixture as measured 
by sunburn cell formation and/or erythema. With the 
objective of determining if a stable topical formulation of 
15% L-ascorbic acid, 1% α-tocopherol, and 0.5% FA could 
protect human skin in vivo from substantial amounts of 
solar-simulated UV radiation, this mixture and its vehicle 
were applied to separate patches of normal-appearing 
human skin for 4 days. Each patch was irradiated with solar-
simulated UV irradiation, 2 to 10 MED, at 2-MED intervals, 
and one day later the skin was evaluated for erythema 
and sunburn cells, as well as immunohistochemically for 
thymine dimers and p53. UV-induced cytokine formation 
and tumor necrosis factor-α were evaluated by real-time 
PCR. The results showed that the antioxidant mixture lotion 
provided significant photoprotection for skin according 
to all evaluation methods and its mechanism of action is 
different from sunscreens, suggesting that they can be used 
as a supplement to conventional sun protectors (Murray et 
al., 2008).
Oresajo et al. (2008) evaluated the protective effects 
of a topical antioxidant mixture containing vitamin C, FA 
and phloretin against ultraviolet-induced photodamage in 
human skin using biomarkers of skin damage. Ten human 
subjects (18-60 years old; Fitzpatrick skin types II and III) 
were randomized and treated with the antioxidant product 
or vehicle control on the lower back for four consecutive 
days. On day 4, the two test sites received solar-simulated 
UV irradiation, and on day 5 digital images were taken 
and biopsies collected from the two test sites, as well 
as a control site from each subject for morphology and 
immunohistochemical studies. Pretreatment of skin 
with the antioxidant composition limited the increase 
of the erythema, sunburn cell formation and p53 protein 
expression. As in the above mentioned case, this study 
confirmed the protective role of a unique mixture of 
antioxidants containing vitamin C, FA, and phloretin on 
human skin from the harmful effects of UV irradiation and 
may be proposed as a sunscreen complement for providing 
photoprotection to human skin.
Radioprotective agent
Radioprotectors are antioxidants that have the 
ability to balance the free radicals produced by incidence 
of ionizing radiation offering some degree of protection 
for living tissues (Aruoma et al., 1989). Today a number 
of radioprotective substances have been researched that 
reduce the negative effects caused by exposure to ionizing 
radiation. Even with a mechanism of action that has not 
yet been fully elucidated, several authors reported in the 
literature that their protective role is related to chemical 
bonding with certain enzymes that are activated by these 
substances and free radicals (Malinda, Kleinman, 1996). 
The ranges of molecules that can act as radioprotectors, 
with the exception of synthetic substances, are commonly 
found in foods such as fruits, vegetables and meat (Aruoma 
et al., 1989). Thus, FA may be included among potentially 
radioprotective molecules (Kanski et al., 2002; Graf, 1992).
Srinivasan et al. (2006) evaluated the protective 
effects of FA in hepatocytes isolated from the liver of 
rats exposed to gamma radiation. Pretreatment of cells 
with 1, 5 and 10 mg FA/mL significantly decreased DNA 
damage, the generation of ROS and increased levels of 
antioxidant enzymes, suggesting that FA has potential for 
use in radiotherapy as a radioprotective agent.
Studies in rats have shown that intraperitoneal 
administration of 50, 75 and 100 mg FA/kg body weight 
1 h before exposure to gamma radiation (4 Gy) found 
a decrease in yield of DNA strand breaks in murine 
peripheral blood leukocytes and bone marrow cells 
(Maurya et al., 2006). The dose of 50 mg of FA/kg body 
weight resulted in faster disappearance of DNA strand 
breaks than the group of mice that received no FA. 
Janakiraman et al. (2012) repeated the same experiment, 
supplying 50 mg FA/kg body weight once daily for five 
consecutive days. One hour after the last administration 
of FA on the sixth day, the whole body of the animals was 
exposed to gamma radiation of 8 Gy and the effects of FA 
pretreatment on radiation-induced changes in antioxidant 
enzymes and lipid peroxidation status in spleen, liver and 
intestine were analyzed. Pretreatment with FA significantly 
increased activity of antioxidant enzymes, including the 
superoxide dismutase, catalase and glutathione peroxidase 
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at 24 h post irradiation. Using the comet assay, it was 
observed that FA pretreatment significantly decreased 
the percentage of tail DNA, tail length, tail moment and 
Olive tail moment in the peripheral blood of mice whose 
entire body was submitted to radiation. The histological 
observations indicated a decline in the villus height and 
crypt number with an increase in goblet and dead cell 
population in the irradiated group, which was normalized 
by FA pretreatment. These studies indicated that FA 
treatment prevents radiation-induced lipid peroxidation, 
DNA damage and restored antioxidant status and 
histopathological changes in experimental animals, 
suggesting that it may be adjuvant in radiotherapy to 
protect normal tissues from gamma-radiation damage.
CONCLUSIONS
Ferulic acid and some derivatives have been 
proven to be effective antioxidant, anti-microbial, 
anti-inflammatory, hepatoprotective, neuroprotective, 
anticarcinogenic, anti-diabetic, anti-cholesterolemic, UV-
protective and radioprotective compounds. Most of the 
diverse pharmacological properties of FA may be associated 
with its ability of break free radical chain reactions, 
but not all. The positive effects of FA on HMG-CoA 
reductase, glucokinase and antioxidant and detoxification 
gene expression suggest additional properties whose 
mechanisms deserve further investigation. The noteworthy 
pharmacological properties of FA – wide array of 
therapeutic applications and lack of side known effects – 
make it an interesting compound for use as a functional 
food as well as a substitute to synthetic drugs. However, 
the large number of in vitro and animal tests contrasts 
with the lack of clinical trials, preventing the use of FA in 
human health both as a nutrient supplement as well as a 
therapeutic drug against human diseases.
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